ARC-101: An Investigational CLDN6-Targeted Bispecific T-Cell Engager for Solid Tumors

1. Executive Summary

ARC-101 is an investigational bispecific T-cell engaging (TCE) antibody developed by Third Arc Bio Inc., currently undergoing Phase 1 clinical evaluation for the treatment of Claudin 6 (CLDN6)-positive solid tumors.[1] The molecule is designed to dually target CLDN6, an oncofetal antigen predominantly expressed on tumor cells, and the CD3 epsilon (CD3ε) component of the T-cell receptor complex on T-lymphocytes.[3] This engagement aims to redirect cytotoxic T-cells to mediate the lysis of CLDN6-expressing cancer cells. Preclinical studies have highlighted ARC-101's high specificity for CLDN6, potent cytolytic activity, a long pharmacokinetic half-life, and optimal biophysical properties, positioning it as a potential best-in-class therapeutic agent.[1]

The selection of CLDN6 as a target is based on its highly restricted expression profile, being largely absent in normal adult tissues but frequently re-expressed in various malignancies, including ovarian and testicular cancers.[3] This differential expression is anticipated to provide a favorable therapeutic window. The ongoing first-in-human Phase 1 clinical trial (NCT06672185; ARC101-P1-101) is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of ARC-101 in patients with advanced CLDN6-expressing solid tumors.[2]

The consistent emphasis on ARC-101's "best-in-class" potential throughout its early communications suggests a strategic positioning by Third Arc Bio.[1] This claim appears to be founded on differentiated characteristics, particularly its remarkable specificity for CLDN6 over other highly homologous Claudin family members, which could translate to an improved therapeutic index compared to other CLDN6-targeted or TCE therapies.[2] Such specificity is crucial for minimizing off-target toxicities, a common challenge for immunotherapies. Furthermore, ARC-101's development serves as a critical validation for Third Arc Bio's broader "Synergy Platform," which aims to develop novel multifunctional antibodies, including those targeting CD3 and CD28 for enhanced T-cell co-stimulation.[2] The clinical performance of ARC-101 will therefore not only determine its own future but also significantly influence the perceived viability of the company's underlying antibody engineering technologies and subsequent pipeline candidates.

2. Introduction to ARC-101

ARC-101, also referred to as ARC 101, is an investigational therapeutic agent developed by Third Arc Bio Inc., a clinical-stage biotechnology company focused on novel antibody-based therapies.[1]

ARC-101 is classified under several scientific and therapeutic categories, reflecting its complex nature and intended application. It is a bispecific antibody, engineered to concurrently bind to two distinct antigens: CLDN6 on the surface of tumor cells and CD3 on T-cells.[2] This dual-binding capability defines its function as a T-cell Engager (TCE), a class of molecules designed to redirect the host's T-lymphocytes to recognize and eliminate cancer cells.[1] Consequently, ARC-101 falls under the broader categories of immunotherapy and antineoplastics, indicating its mechanism of harnessing the immune system to combat cancer.[3] More specifically, it is described as a T lymphocyte modulator due to its direct action on T-cell activity.[7] ARC-101 is recognized as a New Molecular Entity (NME), signifying that its active moiety has not been previously approved by regulatory authorities.[7] This NME status is of considerable importance, as it typically confers a period of market exclusivity upon regulatory approval, providing an incentive for the extensive research and development investment required for novel therapeutics.

The multiple classifications of ARC-101 underscore its sophisticated design, which integrates advanced antibody engineering with immuno-oncology principles. The bispecific nature allows for targeted delivery of T-cell-mediated cytotoxicity, while its identity as a TCE places it within a rapidly evolving class of cancer immunotherapies.

Table 1: Key Characteristics of ARC-101

Characteristic	Description	Key Sources
Official Name	ARC-101	1
Developer	Third Arc Bio Inc.	2
Drug Type	Bispecific Antibody, T-Cell Engager (TCE)	2
Targets	Claudin 6 (CLDN6) on tumor cells, CD3 on T-cells	3
Proposed Indication Area	CLDN6-positive Solid Tumors	1
Key Claimed Attributes	Potential best-in-class, high specificity for CLDN6, potent cytotoxicity, long half-life, optimal biophysical properties, no off-target binding	1
Current Development Phase	Phase 1 Clinical Trial (NCT06672185)	2
NME Status	Yes	7

3. The Target: Claudin 6 (CLDN6)

Claudin 6 (CLDN6) is the molecular target of ARC-101 and is increasingly recognized as a highly promising antigen for cancer immunotherapy due to its distinct expression profile.

3.1. CLDN6 as an Oncofetal Antigen

CLDN6 is characterized as an oncofetal protein.3 This classification signifies that its expression is physiologically prominent during embryonic development but is subsequently downregulated and largely absent in most normal, healthy adult tissues.5 Critically, CLDN6 expression is frequently reactivated in various types of cancer cells.1 This differential expression pattern—high in tumors and low to negligible in normal adult tissues—forms the cornerstone of its attractiveness as a therapeutic target. The premise is that therapies directed against CLDN6 can selectively attack cancer cells while sparing healthy cells, thereby potentially minimizing on-target, off-tumor toxicities and leading to a wider therapeutic window.5

3.2. Expression Profile of CLDN6

The therapeutic rationale for targeting CLDN6 is strongly supported by its observed expression patterns:

• Normal Adult Tissues: CLDN6 expression is reported as negligible or nearly absent in most healthy adult tissues.[5] Studies indicate it is selectively expressed during embryonic development and becomes largely undetectable in normal adult tissues postnatally.[10] More specifically, CLDN6-positive epithelial progenitors have been detected primarily during the initial few weeks of life, with their presence diminishing as epithelia terminally differentiate.[12] This transient postnatal expression in progenitor cells is a nuanced aspect of CLDN6 biology that warrants careful consideration in the development of CLDN6-targeted therapies. While the oncofetal nature is highly advantageous for specificity, the existence of these progenitor cells, however transient or scarce, necessitates thorough preclinical safety assessments and potentially careful patient monitoring to mitigate any risk of toxicity related to unexpected expression in adult progenitor cell niches or during tissue regeneration processes.
• Cancerous Tissues: In stark contrast to its silence in normal adult tissues, CLDN6 is aberrantly upregulated or re-expressed in a variety of solid tumors.[1] This re-expression has been documented in numerous cancer types, including ovarian cancer, testicular cancer (germ cell tumors), endometrial cancer, gastric cancer, non-small cell lung cancer (NSCLC), desmoplastic small round cell tumors (DSRCTs), and Wilms tumors.[5] Furthermore, CLDN6 expression has been associated with a poor prognosis in some cancer types, suggesting it may not merely be a passive surface marker but could potentially contribute to tumor aggressiveness or resistance to standard therapies.[5] If CLDN6 indeed plays an active role in adverse tumor biology, targeting it could offer dual benefits: direct tumor cell killing and neutralization of a factor contributing to poor outcomes.

Table 2: CLDN6 Expression in Selected Tumor Types and Normal Tissues

Tissue Type	CLDN6 Expression Level/Frequency	Key Sources
Ovarian Cancer	Expressed, High in some subtypes (e.g., serous)	5
Testicular Cancer / Germ Cell Tumors	Expressed, Uniformly high prevalence in some GCTs	8
Endometrial Cancer	Expressed	5
Gastric Cancer	Expressed	5
Non-Small Cell Lung Cancer (NSCLC)	Expressed	5
Desmoplastic Small Round Cell Tumors	Strong and homogeneous expression	12
Wilms Tumors	Heterogeneous expression (absent in blastemal component)	12
Pancreatic Cancer	Expressed	5
Breast Cancer	Expressed	5
Normal Adult Tissues	Negligible, Nearly absent, Undetectable	5
Embryonic Tissues / Postnatal Progenitors	Selectively expressed during development; transiently in postnatal epithelial progenitors (first few weeks)	10

3.3. Biological Characteristics and Rationale as a Therapeutic Target

CLDN6 is a member of the claudin family of proteins, which are integral components of tight junctions—cellular structures critical for maintaining cell-cell adhesion and regulating paracellular permeability in epithelial and endothelial cell layers.5 CLDN6 itself is reported to play roles in the regulation of epithelial and endothelial cell proliferation and differentiation.5 Structurally, it possesses four transmembrane domains and a PDZ-binding motif at its cytoplasmic C-terminus, enabling interactions with various signaling and cytoskeletal proteins.5 Uniquely among claudin proteins, CLDN6 has been noted for its potential specific involvement in activating cell adhesion signals and regulating nuclear receptor activity.5

The rationale for targeting CLDN6 in oncology is compelling:

• Its highly tumor-restricted expression pattern makes it an ideal tumor-associated antigen (TAA) for therapies like TCEs, as this minimizes the risk of on-target, off-tumor toxicity.[3]
• The high density of CLDN6 antigen on tumor cells and its relatively slow rate of internalization are also considered advantageous properties for antibody-based targeting.[11]

However, developing CLDN6-specific monoclonal antibodies presents a significant technical challenge due to the high degree of sequence homology between CLDN6 and other claudin family members (e.g., CLDN3, CLDN4, CLDN9) that are more broadly expressed in normal tissues.[10] Achieving exquisite specificity for CLDN6 while avoiding cross-reactivity with these other claudins is paramount for safety. The claim that ARC-101 possesses "best-in-class specificity" and avoids other Claudin family proteins suggests that Third Arc Bio has successfully addressed this challenge, which would represent a notable technological advancement and a key differentiator for ARC-101.[1]

4. Mechanism of Action of ARC-101

ARC-101 employs a sophisticated mechanism of action characteristic of a T-cell engaging bispecific antibody, designed to leverage the patient's own immune system to combat cancer.

4.1. T-cell Engager Function and Dual Targeting

ARC-101 is engineered with two distinct antigen-binding sites.3 One arm of the antibody is designed to bind with high specificity and selectivity to CLDN6, which is expressed on the surface of targeted tumor cells.1 The other arm is engineered to bind to the CD3 complex, specifically CD3ε, a critical component of the T-cell receptor (TCR) present on virtually all T-lymphocytes.3 This dual-targeting capability is the hallmark of its function as a T-cell Engager (TCE).1

4.2. Immune Synapse Formation and T-cell Activation

By simultaneously binding to CLDN6 on a cancer cell and CD3 on a T-cell, ARC-101 acts as a molecular bridge, physically linking the effector immune cell (T-cell) to the target tumor cell.3 This forced proximity facilitates the formation of a cytolytic immune synapse between the T-cell and the tumor cell. The engagement of the CD3 complex by ARC-101, in the context of this induced synapse, mimics the first signal of T-cell activation that normally occurs upon TCR recognition of an antigen presented by an MHC molecule. This leads to the activation of the T-cell's cytotoxic machinery.2 Third Arc Bio's broader platform emphasizes the generation of "immune synapses to precisely activate or inhibit T cells," and ARC-101 exemplifies an activating approach within this framework.2 The quality of this engineered synapse is likely a key focus of development, as physiological T-cell activation involves a complex interplay of signals. While ARC-101 is a CLDN6xCD3 bispecific, its development under a platform that also explores CD28 co-stimulation for future molecules suggests an appreciation for the nuances of robust T-cell activation, aiming for more than simple cell tethering.2

4.3. Tumor Cell Lysis

Once activated via ARC-101-mediated engagement, the T-cells unleash their effector functions against the CLDN6-expressing tumor cells. This typically involves the release of cytotoxic granules containing perforin and granzymes, which induce apoptosis (programmed cell death) in the cancer cells, leading to tumor cell lysis.1 Preclinical data for ARC-101 report "potent cytotoxicity" and "potent cytolytic activity," underscoring this intended outcome.1 The observation that this potency is achieved "at low concentrations" is a significant pharmacological attribute.3 High potency implies that a relatively small amount of the drug is required to elicit a therapeutic effect, which can translate to lower administered doses, potentially reducing dose-dependent toxicities and manufacturing demands. This suggests strong binding affinities for both CLDN6 and CD3, and efficient downstream T-cell activation.

4.4. Specificity and Avoidance of Off-Target Effects

A critical aspect of ARC-101's mechanism, and a cornerstone of its "best-in-class" potential, is its high specificity for CLDN6, with a claimed lack of off-target binding and an ability to avoid other Claudin family proteins.1 Given the homology among Claudin proteins, this selectivity is crucial for minimizing the risk of T-cells being directed against healthy tissues that might express other Claudin isoforms, thereby enhancing the therapeutic index (the ratio of efficacy to toxicity).

The efficacy of ARC-101, like other TCEs, inherently depends on the presence and functionality of the patient's T-cells. Factors such as the patient's baseline immune status, the impact of prior cancer therapies on T-cell populations (number, fitness, exhaustion levels), and the immunosuppressive nature of the solid tumor microenvironment could influence clinical outcomes. These considerations may necessitate future exploration of predictive biomarkers related to T-cell health or tumor microenvironment characteristics to optimize patient selection or guide potential combination strategies.

5. Preclinical Development and Findings

The preclinical development of ARC-101 has provided foundational evidence supporting its progression into clinical trials, highlighting key attributes related to its specificity, potency, and pharmacokinetic profile.

5.1. Summary of Key Preclinical Data

• Specificity and Selectivity: A prominent feature emphasized in preclinical reports is ARC-101's high specificity for its target, CLDN6, with no significant off-target binding observed.[1] Crucially, it is reported to effectively discriminate CLDN6 from other closely related Claudin family proteins.[1] This selectivity is paramount for minimizing potential on-target, off-tumor toxicities that could arise from binding to other Claudins expressed on normal tissues.
• Potency and Efficacy: ARC-101 demonstrated potent cytolytic activity in vitro against a panel of CLDN6-expressing tumor cell lines, achieving this effect at low concentrations.[3] This in vitro potency was further substantiated by in vivo efficacy in an ovarian cancer xenograft model, where ARC-101 treatment led to antitumor effects.[3] The choice of an ovarian cancer model for in vivo proof-of-concept is strategically aligned with the known prevalence of CLDN6 in this malignancy and the significant unmet medical need, particularly in recurrent or platinum-resistant disease stages.[5] This preclinical validation provides an early rationale for including ovarian cancer patients in the Phase 1 clinical trial's dose expansion phase.[3]
• Pharmacokinetic (PK) Properties: ARC-101 is reported to possess a long pharmacokinetic half-life in preclinical models.[1] A longer half-life is generally advantageous for therapeutic antibodies, as it can allow for less frequent dosing regimens (e.g., weekly or bi-weekly infusions rather than daily or continuous administration), which improves patient convenience and adherence, while also helping to maintain sustained therapeutic drug concentrations.
• Biophysical Properties: The molecule is described as having optimal biophysical properties.[1] While specific details are not extensively provided in the available summaries, this typically implies favorable characteristics such as good stability, solubility, and manufacturability, which are crucial for successful drug development and commercialization.
• Timeline: Preclinical trials investigating ARC-101 in solid tumors using parenteral administration were conducted in the USA prior to November 2024.[7]

The combination of high specificity, potent cytotoxicity at low concentrations, and a long half-life observed preclinically constitutes a compelling triad of desirable attributes for a T-cell engager. These features collectively suggest the potential for a favorable therapeutic window in clinical application, characterized by robust efficacy against CLDN6-positive tumors, manageable toxicity due to target selectivity, and a convenient dosing schedule for patients.

5.2. AACR 2025 Presentation

Third Arc Bio is scheduled to present preclinical findings for ARC-101 at the American Association for Cancer Research (AACR) Annual Meeting in 2025.2 The presentation will be in the form of an E-poster titled: "Pharmacologic characterization of a highly specific and potent CLDN6xCD3 T cell engager (TCE), ARC101, for the treatment of CLDN6+ cancers," with Sanjaya Singh of Third Arc Bio listed among the authors.16 This presentation is anticipated to provide a more detailed account of the preclinical data, with a particular emphasis on substantiating ARC-101's "best-in-class specificity for CLDN6 versus other closely related Claudin proteins".2 This AACR disclosure represents a significant milestone for Third Arc Bio, offering the broader scientific community the first in-depth look at the preclinical pharmacology that underpins the company's claims about ARC-101's differentiated profile. The specific focus on "specificity" in the poster title itself underscores the critical importance of this attribute to ARC-101's development strategy and competitive positioning.

6. Clinical Development: Phase 1 Trial (NCT06672185 - ARC101-P1-101)

ARC-101 has progressed into clinical development with the initiation of a first-in-human, multicenter, open-label Phase 1 study identified as ARC101-P1-101 (ClinicalTrials.gov Identifier: NCT06672185).[2] This trial marks a significant step for Third Arc Bio, transitioning the company to a clinical-stage entity.[2]

6.1. Study Objectives and Endpoints

The primary objectives of the ARC101-P1-101 study are to determine the optimal dosing regimen for ARC-101, evaluate its safety and tolerability profile in patients with advanced CLDN6-expressing solid tumors, and to establish the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D).2 Primary endpoints include the frequency and type of dose-limiting toxicities (DLTs), the occurrence and severity of adverse events (AEs) and serious adverse events (SAEs), and changes in laboratory values.18

Secondary objectives include the assessment of ARC-101's pharmacokinetic (PK) and pharmacodynamic (PD) characteristics, and the evaluation of its preliminary antitumor efficacy.[2] Secondary efficacy endpoints will encompass metrics such as Overall Response Rate (ORR), Overall Survival (OS), Duration of Response (DOR), and Progression-Free Survival (PFS).[18] The immunogenicity of ARC-101, specifically the number of patients developing anti-drug antibodies (ADAs), will also be assessed as a secondary endpoint.[18]

6.2. Study Design and Methodology

The Phase 1 trial is structured in two main parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).3 The dose escalation phase employs a Bayesian Optimal Interval (BOIN) design, a model-assisted approach intended to optimize dose selection and minimize patient exposure to sub-therapeutic or overly toxic doses.3

• Part 1 (Dose Escalation): This part aims to identify the MTD, RP2D, and the optimal dosing schedule. It commences with an 'Accelerated Titration Phase,' where cohorts of at least one (but no more than three) patients receive ARC-101 via a fixed-dose intravenous (IV) regimen.[3] Toxicity is assessed 21 days after the initial dose.[19] If a single event of clinically significant toxicity of Grade ≥2 is observed, the study transitions to a 'Standard Titration Phase,' enrolling cohorts of at least three patients per ARC-101 target dose level.[3] A notable feature of the trial design is the provision to implement a 'Fractionated Step-up Dosing' IV regimen if immune-related toxicities, such as Cytokine Release Syndrome (CRS), are observed.[3] This proactive strategy, common in TCE development, involves administering the initial doses in smaller, escalating fractions to mitigate the risk and severity of CRS. The design also allows for the enrollment of backfill cohorts and for intra-patient dose escalations under specific conditions.[3]
• Part 2 (Dose Expansion): Once the RP2D and schedule are determined in Part 1, Part 2 will further investigate the safety, PK/PD profile, and preliminary antitumor efficacy of ARC-101 at this established dose. This expansion phase will specifically focus on patients with testicular cancer and ovarian cancer.[3] The selection of these tumor types for expansion is strategically sound, reflecting the known high prevalence of CLDN6 expression in these cancers and early clinical signals of CLDN6-targeted therapies in these indications.[5]

The study is non-randomized with sequential assignment of participants to dose cohorts.[19] ARC-101 is administered as a monotherapy via IV infusion.[2]

6.3. Patient Population and Eligibility Criteria

The trial is enrolling adult patients (≥18 years of age) with locally advanced or metastatic solid tumors that are confirmed to express CLDN6.3 This includes, but is not limited to, ovarian cancer, testicular cancer, or other CLDN6-positive malignancies.8 Patients must have received standard therapy for their advanced or metastatic disease and have either progressed or become refractory to it.3

Key inclusion criteria comprise an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, measurable or evaluable disease according to RECIST v1.1 criteria, and adequate organ function.[3] A mandatory requirement is the provision of a pre-study tumor tissue sample for immunohistochemistry (IHC) analysis of CLDN6 expression.[3] This will facilitate an exploratory objective of correlating CLDN6 expression levels with treatment response, a crucial step for potential future biomarker development and patient selection strategies. Such a biomarker could potentially evolve into a companion diagnostic if a strong correlation is established.

Key exclusion criteria include active central nervous system (CNS) involvement, a diagnosis of another malignancy within two years prior to the first dose of ARC-101, uncontrolled ascites, unresolved Grade >1 toxicity from prior anticancer therapy, clinically significant pulmonary compromise, and active autoimmune disease within 12 months prior to enrollment.[20] Female participants who are pregnant, breastfeeding, or plan to become pregnant, and male participants who plan to father a child during the study or within 90 days after the final administration of the study drug, are also excluded.[20]

6.4. Current Status, Enrollment, and Timeline

The ARC101-P1-101 study is currently active and recruiting participants.3 The first patient was dosed in March 2025.2 The estimated enrollment for the trial is approximately 70 participants across both parts of the study.19 Study sites are located in Australia, including facilities in Queensland, South Australia, and Victoria.8 The estimated primary study completion date is August 1, 2028.18

Table 3: Phase 1 Clinical Trial (NCT06672185 / ARC101-P1-101) Summary

Parameter	Details	Key Sources
Trial Identifier	NCT06672185 / ARC101-P1-101	3
Phase	1	2
Title	A first-in-human phase 1 study of ARC101, a next generation T cell engager (TCE), in patients with advanced solid tumors	3
Sponsor	Third Arc Bio	8
Primary Objectives	Evaluate safety, tolerability; determine MTD and/or RP2D	2
Key Secondary Objectives	Assess PK, PD, and preliminary antitumor efficacy	2
Design	Open-label, multicenter, non-randomized, sequential assignment. Part 1: Dose Escalation (BOIN design, Accelerated/Standard Titration, potential Fractionated Step-up Dosing). Part 2: Dose Expansion.	3
Patient Population	Adults (≥18 years) with locally advanced or metastatic CLDN6-expressing solid tumors (including ovarian, testicular, and others) who have received prior standard therapy. ECOG PS 0-1. Measurable/evaluable disease. Adequate organ function.	3
No. of Patients	Approximately 70	19
Intervention	ARC-101 administered as an intravenous (IV) monotherapy	2
Status	Active, Recruiting (First patient dosed March 2025)	3
Key Locations	Australia (QLD, SA, VIC)	8
Est. Primary Completion	August 1, 2028	18

7. Potential Therapeutic Indications

ARC-101 is being developed for the treatment of solid tumors that express the CLDN6 antigen.[1] The broad eligibility criteria in the ongoing Phase 1 trial reflect an initial strategy to evaluate ARC-101 across a range of CLDN6-positive malignancies, with a more focused approach planned for the dose expansion phase.

7.1. Primary Focus: CLDN6-Positive Solid Tumors

The overarching therapeutic indication for ARC-101 is patients with locally advanced or metastatic solid tumors whose cancer cells express CLDN6.2 This target-driven approach is central to the drug's development strategy, aiming to deliver efficacy specifically in tumors harboring the antigen.

7.2. Specific Cancer Types of Interest

While the dose escalation phase of the ARC101-P1-101 trial is open to a variety of CLDN6-expressing solid tumors, the dose expansion phase will specifically concentrate on:

• Ovarian Cancer: This is a key indication due to the frequent expression of CLDN6 in ovarian malignancies, particularly certain subtypes, and the significant unmet medical need in advanced and recurrent settings.[3]
• Testicular Cancer (Germ Cell Tumors): CLDN6 is also known to be highly and often uniformly expressed in testicular germ cell tumors, making this another priority indication for ARC-101 development.[3]

The inclusion of "other Claudin 6+ cancers" in the dose escalation phase suggests an element of a "basket trial" design.[19] This approach allows for the potential observation of efficacy signals in diverse tumor histologies that express CLDN6, beyond the initial focus on ovarian and testicular cancers. Such findings could open avenues for future development in less common but CLDN6-positive malignancies.

7.3. Other Potential CLDN6-Positive Cancers

Based on reported CLDN6 expression data, other cancer types that could potentially benefit from ARC-101, should its efficacy and safety be established, include:

• Endometrial Cancer [5]
• Non-Small Cell Lung Cancer (NSCLC) [5]
• Gastric Cancer [5]
• Desmoplastic Small Round Cell Tumors (DSRCTs) [12]
• Wilms Tumors [12]
• Pancreatic Cancer [5]
• Breast Cancer [5]

The potential to treat pediatric cancers like DSRCTs and Wilms tumors, where CLDN6 is reported to be expressed and where its expression in normal postnatal tissues is transient and limited, is particularly noteworthy.[12] These cancers often have limited therapeutic options, especially in relapsed or refractory states. If ARC-101 demonstrates a favorable safety profile and efficacy in adults, and if the CLDN6 expression patterns in pediatric normal tissues are confirmed to offer a safe therapeutic window, pediatric investigations could become a significant future direction. This could lead to orphan drug designations or accelerated approval pathways for specific, high-need pediatric indications.

8. Regulatory Status

As an investigational agent in the early stages of clinical development, ARC-101 has not yet received marketing authorization from any regulatory agency.

• Current Investigational Status: ARC-101 is currently in Phase 1 clinical development.[2] This is the initial phase of human testing, primarily focused on evaluating safety, determining appropriate dosing, and identifying potential side effects.
• Food and Drug Administration (FDA, USA): There are no FDA-approved products for ARC-101 developed by Third Arc Bio.[22] It is important to distinguish Third Arc Bio's ARC-101 (a T-cell engager for cancer) from AR101 developed by Aimmune Therapeutics (an oral immunotherapy for peanut allergy), which did receive FDA Breakthrough Therapy Designation.[23] These are unrelated products.
• European Medicines Agency (EMA): There is no information available in the provided materials regarding any submissions to or approvals from the EMA for Third Arc Bio's ARC-101. Similarly, information pertaining to Aimmune's AR101 MAA submission to the EMA is not relevant to Third Arc Bio's ARC-101.[24] General information on cell and gene therapy approvals by the EMA does not specifically mention ARC-101.[25]
• Pharmaceuticals and Medical Devices Agency (PMDA, Japan): No information is available regarding PMDA review or approval of ARC-101.[26]
• Orphan Drug Status: As of March 2025, ARC-101 has not been assigned Orphan Drug Designation by regulatory bodies.[7]

The absence of regulatory approvals is standard for a drug at the Phase 1 stage of development. Key future regulatory milestones would typically include End-of-Phase-1 meetings with agencies like the FDA to discuss the results and plans for Phase 2 development. Should ARC-101 demonstrate compelling early clinical activity, particularly in indications with high unmet medical need, Third Arc Bio could potentially apply for expedited regulatory programs such as Fast Track designation or Breakthrough Therapy designation.

The current lack of Orphan Drug Status might reflect the initial broad target patient population of "CLDN6+ solid tumors".[7] However, if ARC-101 shows particular promise in specific rare cancer types where CLDN6 is prevalent (e.g., certain subtypes of germ cell tumors or DSRCTs), applications for Orphan Drug Designation for those specific indications could be pursued in the future. Such designations offer various development incentives, including market exclusivity and financial benefits.

9. Developer Profile: Third Arc Bio

Third Arc Bio Inc. is the developer of ARC-101 and is a clinical-stage biotechnology company headquartered in Spring House, Pennsylvania, USA.[2] The company is dedicated to the development of novel multifunctional antibodies designed for a range of indications in oncology and immunology & inflammation (I&I).[2]

9.1. Mission and Technology Focus

Third Arc Bio's core mission is to create innovative multifunctional antibodies that can precisely modulate T-cell activity by generating productive immune synapses.2 The company aims to deliver superior biologic therapeutics characterized by best-in-class T-cell engagement, leveraging novel technologies to address complex diseases.4 This approach signifies an ambition to advance beyond conventional antibody therapies by engineering molecules with more sophisticated mechanisms of action.

9.2. Proprietary Technology Platforms

Third Arc Bio has established distinct technology platforms to underpin its drug discovery and development efforts:

• Third Arc Bio Discovery Engine: This is a comprehensive antibody discovery platform focused on identifying and optimizing T-cell engagers. It employs proprietary immunization techniques, advanced selection algorithms, and sophisticated antibody engineering to pair optimal antigen binders with appropriate antibody architectures. The engine emphasizes careful epitope selection to achieve desired mechanisms of action, high target specificity, superior biophysical properties (enhancing manufacturability and stability), and finely tuned T-cell effector domains. This includes the development of proprietary anti-CD3 and anti-CD28 agonists for T-cell engagers and novel checkpoint agonists for precise immune regulation in I&I indications.[15]
• Synergy Platform (also referred to as ARCStim Platform - Oncology): This platform is dedicated to developing therapies for solid tumors. It leverages the principle of T-cell co-stimulation, primarily through the engagement of CD3 and CD28 pathways, to maximize antitumor efficacy while aiming to minimize systemic toxicity.[2] The Synergy Platform is generating a pipeline of novel multispecific antibodies targeting CD3 and CD28.[2] A key innovation within this platform is the development of conditionally active CD28 co-stimulation, where CD28 binders are designed to be functionally silent on their own and only provide co-stimulatory Signal 2 in the presence of CD3-mediated Signal 1.[15] This conditional activity is intended to focus potent T-cell activation within the tumor microenvironment. The platform supports both two-molecule bispecific approaches and single-molecule trispecific formats, allowing flexibility in molecular design based on the target's characteristics and the desired clinical strategy.[15]
• Tethering Platform (also referred to as ARCTag Platform - Immunology & Inflammation): This platform is focused on I&I diseases and aims to achieve precision immune regulation.[2] It seeks to overcome the limitations of current systemic immunosuppressive treatments by developing multispecific antibodies that can home to diseased tissues and locally suppress harmful immune cell activity, thereby sparing systemic immunity and potentially improving the therapeutic index.[15] These biologics are designed to cluster at the site of autoimmune activity to block pathogenic immune responses.[15]

9.3. ARC-101's Position in the Pipeline

ARC-101 is Third Arc Bio's lead therapeutic candidate and its first bispecific antibody to enter clinical trials.2 Its progression into Phase 1 development signifies the company's transition into a clinical-stage organization.2 ARC-101 is a product of the company's discovery engine and serves as a foundational program for the Synergy/ARCStim Platform.2 The clinical data generated by ARC-101 will be pivotal, not only for the future of this specific CLDN6-targeted program but also as an important clinical validation of Third Arc Bio's underlying antibody engineering capabilities and its broader strategy for developing next-generation multifunctional immunotherapies. Positive outcomes would de-risk subsequent, potentially more complex, candidates emerging from their platforms.

9.4. Leadership

Peter F. Lebowitz, MD, PhD, serves as the Chief Executive Officer and Chief Medical Officer of Third Arc Bio, guiding the company's strategic and clinical development efforts.2

10. Contextual Landscape

The development of ARC-101 occurs within a dynamic and increasingly competitive landscape of therapies targeting CLDN6, as well as in the context of established and evolving standards of care for its potential indications, notably ovarian and testicular cancers.

10.1. Other CLDN6-Targeted Therapies

CLDN6 has emerged as a highly attractive target in oncology, prompting the development of various therapeutic modalities by multiple pharmaceutical and biotechnology companies. This broad interest validates CLDN6 as a bona fide tumor antigen. Key approaches include:

• Antibody-Drug Conjugates (ADCs):
• DS-9606 (Daiichi Sankyo): A humanized anti-CLDN6 monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD) payload. Phase 1 study (NCT05394675) has shown preliminary activity in CLDN6-expressing solid tumors, including germ cell tumors.[5]
• TORL-1-23 (TORL BioTherapeutics): A CLDN6-directed ADC utilizing a monomethyl auristatin E (MMAE) payload via a cleavable linker. Phase 1 trial (NCT05103683) has reported responses in ovarian, testicular, endometrial, and NSCLC patients. A registrational Phase 2 study is planned for platinum-resistant ovarian cancer.[5]
• CLDN6-23-ADC (Unnamed developer in snippet): A fully humanized anti-CLDN6 antibody conjugated to MMAE, showing preclinical efficacy and currently in Phase 1 development.[14]
• CAR T-cell Therapy:
• BNT211 (BioNTech): This approach combines CLDN6-targeting CAR T-cells with a CLDN6 CAR-T-amplifying RNA vaccine (CARVac). A Phase 1/2 study (NCT04503278) has demonstrated antitumor responses in patients with testicular and ovarian cancer.[5]
• Other T-Cell Engagers (TCEs):
• CTIM-76 (Context Therapeutics/Integral Molecular): A CLDN6 x CD3 bispecific antibody. A Phase 1 trial is evaluating CTIM-76 in patients with recurrent CLDN6-positive ovarian, endometrial, and testicular cancer.[11]
• XmAb541 (Xencor): A CLDN6 x CD3 bispecific antibody utilizing Xencor's XmAb® 2+1 format. A Phase 1 study is ongoing in patients with germ cell tumors and other advanced CLDN6-positive solid tumors.[28]
• SAIL66 (Developer not specified): A preclinical stage trispecific TCE designed to bind CLDN6, CD3, and the co-stimulatory molecule CD137, with the aim of enhancing T-cell activation and antitumor efficacy.[10]

Table 4: Comparison of Selected CLDN6-Targeted Therapies in Development

Drug Name (Developer)	Modality	Specific Targets / Payload	Highest Development Phase (Known)	Key Indications Being Studied	Notable Features/Reported Efficacy Snippets	Key Sources
ARC-101 (Third Arc Bio)	Bispecific TCE	CLDN6 x CD3	Phase 1	CLDN6+ Solid Tumors (Ovarian, Testicular cancer focus in expansion)	Potential best-in-class specificity, long half-life, potent cytotoxicity.	1
DS-9606 (Daiichi Sankyo)	ADC	CLDN6 + PBD payload	Phase 1	Advanced/metastatic CLDN6+ solid tumors (incl. GCT)	Confirmed objective responses.	5
TORL-1-23 (TORL BioTherapeutics)	ADC	CLDN6 + MMAE payload	Phase 1 (Phase 2 planned)	Advanced solid tumors (Ovarian, Testicular, Endometrial, NSCLC)	ORR 50% (2.4mg/kg), 42% (3.0mg/kg) in CLDN6+ platinum-resistant ovarian cancer.	5
BNT211 (BioNTech)	CAR T-cell + RNA Vaccine (CARVac)	CLDN6 (CAR-T), CLDN6 (vaccine)	Phase 1/2	Relapsed/refractory CLDN6+ solid tumors (Testicular, Ovarian)	ORR 51.5% with CAR-T + vaccine (1x10^8 cells, lymphodepletion).	5
CTIM-76 (Context Therapeutics/Integral Molecular)	Bispecific TCE	CLDN6 x CD3	Phase 1	Recurrent Ovarian, Endometrial, Testicular cancer	Preclinical complete responses in ovarian xenografts.	11
XmAb541 (Xencor)	Bispecific TCE (XmAb 2+1)	CLDN6 x CD3	Phase 1	Germ Cell Tumors, other CLDN6+ solid tumors	XmAb 2+1 format for avid tumor targeting.	28
SAIL66 (Undisclosed)	Trispecific TCE	CLDN6 x CD3 x CD137	Preclinical	CLDN6+ solid tumors (e.g., Ovarian)	Potential for enhanced T-cell activation via CD137 co-stimulation.	10

This competitive environment underscores the scientific interest in CLDN6. For ARC-101 to carve out a successful niche, it will need to demonstrate clear advantages, likely focusing on its purported superior specificity translating into a better safety profile, or enhanced efficacy, or favorable pharmacokinetics allowing for more convenient dosing compared to its competitors.

10.2. Standard of Care Considerations and ARC-101's Potential Fit

• Advanced/Metastatic CLDN6-positive Ovarian Cancer: The standard of care (SoC) for advanced ovarian cancer typically involves surgical debulking followed by platinum-based chemotherapy (e.g., carboplatin and paclitaxel).14 However, a majority of patients eventually experience relapse, and many develop platinum-resistant disease, which has a poor prognosis and limited treatment options.14 Immune checkpoint inhibitors (ICIs) have shown limited efficacy in unselected ovarian cancer populations, particularly in "cold" tumors like high-grade serous ovarian carcinoma.10 CLDN6-targeted therapies are emerging as promising options in this setting. For instance, the ADC TORL-1-23 has reported objective response rates of 42-50% in CLDN6-positive platinum-resistant ovarian cancer, and BNT211 (CAR-T + vaccine) has also shown responses.5 ARC-101's Potential Fit: ARC-101 could offer a novel immunotherapeutic approach for CLDN6-positive ovarian cancer, particularly in the relapsed/refractory setting where unmet medical need is high. Its success will depend on its efficacy and safety profile relative to other emerging CLDN6 agents and existing salvage therapies. If its specificity translates to better tolerability, it might be suitable for patients who cannot tolerate more aggressive treatments or could be a candidate for combination therapies.
• Advanced/Metastatic Testicular Cancer (Germ Cell Tumors - GCTs): Testicular GCTs are highly curable, even in metastatic settings, with cisplatin-based combination chemotherapy regimens forming the backbone of first-line treatment.29 According to NCCN guidelines, for metastatic nonseminoma GCTs (NSGCT), first-line therapy typically involves 3 cycles of BEP (Bleomycin, Etoposide, Cisplatin) or 4 cycles of EP (Etoposide, Cisplatin) for good-risk disease, and 4 cycles of BEP or VIP (Etoposide/Vinblastine, Ifosfamide, Cisplatin) for intermediate- or poor-risk disease.31 Management of residual masses post-chemotherapy often involves surgical resection (e.g., RPLND), and if viable GCT is found, additional chemotherapy may be given.31 For relapsed or refractory GCTs, options include second-line conventional-dose chemotherapy (e.g., TIP - Paclitaxel, Ifosfamide, Cisplatin; or VeIP - Vinblastine, Ifosfamide, Cisplatin) or high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT).31 Third-line options are more limited and may include further palliative chemotherapy or clinical trials.31 ESMO guidelines similarly emphasize cisplatin-based chemotherapy and multimodal approaches.29 ARC-101's Potential Fit: Given the high efficacy of first-line chemotherapy in GCTs, ARC-101 and other CLDN6-targeted therapies are most likely to be investigated in the relapsed/refractory population. This is a group with a significant unmet medical need, as outcomes diminish with successive lines of therapy. The high and uniform expression of CLDN6 in many GCTs makes it a particularly relevant target.11 The inclusion of testicular cancer in ARC-101's Phase 1 dose expansion cohort confirms the intent to explore its utility in this challenging patient population.3

The development of multiple CLDN6-targeted agents could also pave the way for future combination strategies if single-agent activity is promising but not curative, or if resistance mechanisms emerge. Combining agents with different mechanisms of action (e.g., a TCE with an ADC, or a CLDN6-targeted agent with another immunotherapy) is a common paradigm in oncology, though such strategies for ARC-101 are speculative at this early stage.

11. Summary of Key Attributes and Clinical Potential

ARC-101 emerges from preclinical and early clinical development information as a T-cell engager with several noteworthy attributes that may differentiate it and define its clinical potential.

11.1. Differentiating Features:

• High Specificity for CLDN6: Repeatedly emphasized is ARC-101's remarkable specificity for CLDN6, with an ability to avoid binding to other closely related Claudin family proteins.[1] This is a critical feature, as off-target binding to other Claudins expressed on normal tissues could lead to significant toxicity. This high degree of selectivity is foundational to the claim of a potentially superior therapeutic index.
• Potent Cytolytic Activity: Preclinical studies have demonstrated that ARC-101 can induce potent lysis of CLDN6-expressing tumor cells, both in vitro and in in vivo xenograft models.[1] This activity at low concentrations suggests efficient T-cell redirection and activation.
• Favorable Pharmacokinetic and Biophysical Properties: ARC-101 is reported to have a long pharmacokinetic half-life and optimal biophysical properties.[1] A long half-life can translate to more convenient dosing schedules for patients (e.g., less frequent infusions) and sustained therapeutic exposure. Optimal biophysical properties typically imply good stability, solubility, and manufacturability, which are crucial for drug development and commercial viability.
• Development by Specialized Platform: ARC-101 is the lead candidate from Third Arc Bio's "Synergy Platform" (or ARCStim Platform), which is focused on developing advanced multifunctional antibodies, including those incorporating CD28 co-stimulation signals to enhance T-cell responses.[2] This suggests a design philosophy aimed at creating more sophisticated and potentially more effective immune engagements.

11.2. Therapeutic Index and Unmet Medical Needs:

The central value proposition for ARC-101 appears to be its potential for a "superior therapeutic index".2 This implies a favorable balance between efficacy and toxicity. If ARC-101's specificity indeed minimizes on-target, off-tumor effects or leads to less severe T-cell engager-associated toxicities (like Cytokine Release Syndrome or neurotoxicity) compared to other agents, it would represent a significant clinical advantage. This could allow for the administration of higher, more effective doses, make the treatment tolerable for a broader range of patients (including potentially frailer individuals), or facilitate its use in combination regimens.

ARC-101 aims to address significant unmet medical needs in patients with advanced CLDN6-expressing solid tumors, particularly those who have become refractory to standard therapies.[3] Indications like platinum-resistant ovarian cancer and relapsed/refractory testicular cancer represent patient populations with limited effective treatment options and poor prognoses. The oncofetal nature of CLDN6 provides a strong rationale for targeted therapy, offering the prospect of potent antitumor activity with a reduced impact on normal, healthy tissues.

The practical implications of "optimal biophysical properties" and a "long half-life" extend beyond scientific interest. Enhanced stability and manufacturability can influence the cost of goods and the reliability of drug supply. A longer half-life, by enabling less frequent dosing, can significantly improve patient quality of life, reduce the burden on healthcare systems, and enhance treatment adherence.

12. Conclusion and Future Outlook

ARC-101 is an investigational bispecific T-cell engaging antibody that holds considerable promise as a targeted immunotherapy for CLDN6-positive solid tumors. Its design, emphasizing high specificity for the oncofetal antigen CLDN6 while avoiding other Claudin family members, coupled with potent preclinical cytolytic activity and favorable pharmacokinetic properties, positions it as a potentially differentiated agent in a growing field of CLDN6-directed therapies.[1] As the lead clinical candidate for Third Arc Bio, ARC-101 also serves as an important validation of the company's antibody engineering platforms and its broader strategy in developing next-generation multifunctional immunotherapies.[2]

The ongoing Phase 1 clinical trial (NCT06672185) will be critical in translating these preclinical attributes into human clinical benefit. Key anticipated next steps include the completion of the dose escalation phase to determine the recommended Phase 2 dose (RP2D) and schedule, followed by data readouts from the dose expansion cohorts, particularly in ovarian and testicular cancers.[3] These results will provide the first human data on ARC-101's safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy. Further presentations of these data at major scientific conferences will be crucial for disseminating findings to the medical community.

Looking further ahead, successful Phase 1 outcomes would likely lead to the planning and initiation of Phase 2 studies in selected CLDN6-positive tumor types. Depending on the strength of the monotherapy data and the evolving treatment landscape, future exploration of ARC-101 in combination regimens may also be considered. The development pathway for a Phase 1 asset is inherently long, with the primary completion of the current trial estimated for 2028.[18] However, compelling early clinical data, especially in indications with high unmet need and a clear biomarker (CLDN6 expression), could potentially open avenues for accelerated development programs.

The broader interest and investment in CLDN6 as a therapeutic target by multiple entities using diverse modalities (ADCs, CAR T-cells, other TCEs) are likely to create a positive feedback loop. As more CLDN6-targeted therapies advance and demonstrate clinical utility, awareness and diagnostic testing for CLDN6 expression in relevant tumor types are expected to increase. This, in turn, could expand the identifiable patient pool eligible for CLDN6-directed treatments like ARC-101, facilitating clinical trial recruitment and defining the market for such therapies. The mandatory CLDN6 IHC testing in the ARC-101 trial contributes to this evolving diagnostic landscape.[3]

In summary, ARC-101 represents a carefully designed therapeutic approach targeting a well-validated oncofetal antigen. Its clinical journey is in its early stages, but its preclinical profile suggests it has the potential to offer a meaningful new treatment option for patients with challenging CLDN6-positive cancers. The successful clinical development of ARC-101 would not only benefit patients but also solidify Third Arc Bio's position in the field of innovative antibody therapeutics.

Works cited

1. www.targetedonc.com, accessed June 5, 2025, https://www.targetedonc.com/view/trial-of-arc101-doses-first-patient-with-cldn6-solid-tumors#:~:text=1-,ARC101%2C%20a%20potential%20best%2Din%2Dclass%20T%2Dcell,life%2C%20and%20optimal%20biophysical%20properties.
2. Third Arc Bio Announces First Patient Dosed in Phase 1 Clinical Trial of Lead T Cell Engager ARC101 to Treat CLDN6 Positive Cancers - PR Newswire, accessed June 5, 2025, https://www.prnewswire.com/news-releases/third-arc-bio-announces-first-patient-dosed-in-phase-1-clinical-trial-of-lead-t-cell-engager-arc101-to-treat-cldn6-positive-cancers-302398399.html
3. ARC101-P1-101: A first-in-human phase 1 study of ARC101, a next generation T cell engager (TCE), in patients with advanced solid tumors. - ASCO Publications, accessed June 5, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS2671
4. Third Arc Bio Announces First Patient Dosed in Phase 1 Clinical Trial of Lead T Cell Engager ARC101 to Treat CLDN6 Positive Cancers, accessed June 5, 2025, https://thirdarcbio.com/news/third-arc-bio-announces-first-patient-dosed-in-phase-1-clinical-trial-of-lead-t-cell-engager-arc101-to-treat-cldn6-positive-cancers/
5. CLDN6-Directed Agents Generate Encouraging Early Activity in ..., accessed June 5, 2025, https://www.onclive.com/view/cldn6-directed-agents-generate-encouraging-early-activity-in-solid-tumors
6. Third Arc Bio Begins Dosing First Patient in Phase 1 Trial for ARC101 T Cell Engager in CLDN6 Positive Cancers - Patsnap Synapse, accessed June 5, 2025, https://synapse.patsnap.com/article/third-arc-bio-begins-dosing-first-patient-in-phase-1-trial-for-arc101-t-cell-engager-in-cldn6-positive-cancers
7. ARC 101 - AdisInsight - Springer, accessed June 5, 2025, https://adisinsight.springer.com/drugs/800080373
8. A Phase 1 Study of ARC101 in Advanced Solid Tumors - AdisInsight - Springer, accessed June 5, 2025, https://adisinsight.springer.com/trials/700377903
9. A first-in-human phase 1 study of ARC101, a next generation T cell engager (TCE), in patients with advanced solid tumors. - Larvol Delta, accessed June 5, 2025, https://delta.larvol.com/NewsItem/NewsItemID/20b9add7-5709-4128-a8dc-edd050603c3a/ARC101-P1-101%203a+A+first-in-human+phase+1+study+of+ARC101%202c+a+next+generation+T+cell+engager+(TCE)%202c+in+patients+with+advanced+solid+tumors.
10. jitc.bmj.com, accessed June 5, 2025, https://jitc.bmj.com/content/jitc/12/10/e009563.full.pdf
11. A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors. - ASCO Publications, accessed June 5, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.16_suppl.TPS2685
12. The Chimeric Antigen Receptor T Cell Target Claudin 6 Is a Marker for Early Organ-Specific Epithelial Progenitors and Is Expressed in Some Pediatric Solid Tumor Entities - MDPI, accessed June 5, 2025, https://www.mdpi.com/2072-6694/17/6/920
13. The Chimeric Antigen Receptor T Cell Target Claudin 6 Is a Marker for Early Organ-Specific Epithelial Progenitors and Is Expressed in Some Pediatric Solid Tumor Entities, accessed June 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11940025/
14. Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors, accessed June 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10233360/
15. Third Arc Bio: Powering Superior Immune Synapses, accessed June 5, 2025, https://thirdarcbio.com/
16. AACR 2025: Pharmacologic characterization of a highly specific and potent CLDN6xCD3 T cell engager (TCE), ARC101, for the treatment of CLDN6+ cancers - LarvolClin, accessed June 5, 2025, https://clin.larvol.com/abstract-detail/AACR%202025/75200612
17. A first-in-human phase 1 study of ARC101, a next generation T cell engager (TCE), in patients with advanced solid tumors., accessed June 5, 2025, https://ascopubs.org/doi/pdf/10.1200/JCO.2025.43.16_suppl.TPS2671
18. Trial of ARC101 Doses First Patient With CLDN6+ Solid Tumors, accessed June 5, 2025, https://www.targetedonc.com/view/trial-of-arc101-doses-first-patient-with-cldn6-solid-tumors
19. ARC101 in Advanced Solid Tumors - ClinicalTrials.Veeva, accessed June 5, 2025, https://ctv.veeva.com/study/arc101-in-advanced-solid-tumors
20. ARC101 in Advanced Solid Tumors | Clinical Research Trial Listing - CenterWatch, accessed June 5, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06672185/arc101-in-advanced-solid-tumors
21. This study is recruiting people with advanced solid cancer to evaluate how safe, tolerable and effective a new immunotherapy drug (called ARC101) is - Victorian Cancer Trials Link, accessed June 5, 2025, https://trials.cancervic.org.au/details/vctl_nct06672185
22. ARC-101 - MedPath, accessed June 5, 2025, https://trial.medpath.com/drug/2357f34c8970b12f/arc-101
23. Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101, accessed June 5, 2025, https://www.fiercebiotech.com/biotech/aimmune-therapeutics-receives-fda-breakthrough-therapy-designation-for-ar101
24. Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy - BioSpace, accessed June 5, 2025, https://www.biospace.com/aimmune-submits-marketing-authorization-application-to-european-medicines-agency-for-ar101-for-peanut-allergy
25. Gene, Cell, & RNA Therapy Landscape Report Q4 2024 Quarterly Data Report - ASGCT, accessed June 5, 2025, https://www.asgct.org/global/documents/asgct-citeline-q4-2024-report.aspx
26. Report on the Deliberation Results November 28, 2023 Pharmaceutical Evaluation Division, Pharmaceutical Safety Bureau Ministry o - PMDA, accessed June 5, 2025, https://www.pmda.go.jp/files/000269813.pdf
27. Critical Review of the Determination Process by the Japanese Reviewing Authority in Approving the Additional Efficacy of Fludarabine Phosphate, accessed June 5, 2025, https://ascopubs.org/doi/pdf/10.1200/JCO.2009.23.9020
28. A phase 1, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (claudin-6 x CD3) T-cell engaging bispecific antibody in subjects with germ cell tumors and other advanced solid tumors. | Journal of Clinical Oncology - ASCO Publications, accessed June 5, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.TPS652
29. Management of Testicular Cancer - ASCO Publications, accessed June 5, 2025, https://ascopubs.org/doi/pdf/10.1200/OP-25-00211
30. Testicular Cancer, Version 2.2020, NCCN Clinical Practice ..., accessed June 5, 2025, https://pubmed.ncbi.nlm.nih.gov/31805523/
31. Testicular Cancer, Version 2.2020, NCCN Clinical Practice ... - JNCCN, accessed June 5, 2025, https://jnccn.org/view/journals/jnccn/17/12/article-p1529.xml
32. Key Updates in Testicular Cancer: Optimizing Survivorship and Survival, accessed June 5, 2025, https://ascopubs.org/doi/10.1200/EDBK-25-472654